MAB Discovery

MAB Discovery is a Munich-based antibody discovery company with a proven track record of generating therapeutic mAbs for pharmaceutical partners, with eight partner projects reaching the clinic by 2023. Following the 2019 sale of its laboratory platform to BioNTech, the company restructured, spinning out its proprietary clinical-stage assets into a separate entity, IcanoMAB, which it continues to advance through a network of collaborations. MAB Discovery now operates as an asset-centric entity, leveraging its discovery expertise and network to progress its retained portfolio while maintaining its partner-focused service legacy.

Proprietary antibody discovery platform generating diverse, naturally variable B-cells (>10,000) to produce precision canonical monoclonal antibodies without in vitro maturation. Process includes high-throughput functional screening and sophisticated sequence optimization (humanization, de-immunization, CMC risk mitigation).

MAB Discovery/IcanoMAB competes in the highly crowded antibody therapeutics space against large pharma and well-funded biotechs with advanced platforms (e.g., bispecifics, ADCs). Its focus on 'precision canonical' antibodies is a niche differentiation that must prove superior in clinical efficacy against established engineered approaches.